Background: Diverting colostomy followed by neoadjuvant treatment is a treatment of choice for obstructive rectal cancer. Such patients may be treated via a robotic approach with several advantages over conventional laparoscopic surgery. Conversely, the existing stoma may interfere with the optimal trocar position and thus affect the quality of robotic surgery. Moreover, the console surgeon does not face the patient, which may endanger the stoma.
Methods: Patients with rectal cancer who underwent sphincter-preserving surgery were retrospectively investigated using a robotic platform after neoadjuvant treatment at our hospital. Based on pretreatment stoma creation, patients were divided into the NS (those without a stoma) and S groups (patients with a stoma). Baseline characteristics, types of neoadjuvant treatment, short-term surgical outcomes, postoperative anorectal manometric data, and survival were compared between the groups.
Results: The NS and S groups comprised 65 and 9 patients, respectively. Conversion to laparotomy was required in three patients in the NS group. The S group required a longer console time than the NS group (median: 367 vs. 253 min, respectively, p = 0.038); however, no difference was observed in the total operative time (p = 0.15) and blood loss (p = 0.70). Postoperative complication rates, anorectal function, and oncological outcomes were similar between the groups.
Conclusions: Although console time was longer in patients with a stoma, robotic surgery could be performed safely like in those without a stoma after neoadjuvant treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11322400 | PMC |
http://dx.doi.org/10.1007/s10151-024-02980-w | DOI Listing |
JACC Case Rep
December 2024
Division of Cardiac Surgery, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
Sarcomas represent the most common primary cardiac malignancy. A poor prognosis can be improved with multimodal management including aggressive surgical reconstruction in combination with neoadjuvant or adjuvant therapy. We present the case of a primary cardiac sarcoma to describe our approach to a more radical right atrial and bicaval reconstruction.
View Article and Find Full Text PDFCureus
December 2024
Surgical Oncology, Benazir Bhutto Hospital, Rawalpindi, PAK.
Introduction Breast cancer is considered the most common malignant tumor in women, and incidence rates have risen progressively over the last decades. Modified radical mastectomy (MRM) is an effective treatment option. This research sought to establish the frequency, causes, and distribution of postoperative complications that are associated with MRM in the Pakistani population suffering from breast cancer.
View Article and Find Full Text PDFTech Coloproctol
January 2025
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Background: Neoadjuvant combination immunotherapy is a potential treatment option for patients with proficient mismatch repair/microsatellite stable colorectal cancer. Preoperative screening via endoscopy and imaging examinations could help identify patients who may potentially achieve a complete response after neoadjuvant combination immunotherapy. This study aims to evaluate the diagnostic accuracy of endoscopic and imaging examinations in predicting pathological complete response after neoadjuvant combination immunotherapy.
View Article and Find Full Text PDFJ Gastrointest Cancer
January 2025
Surgical Oncology Department, Oncology Center Mansoura University (OCMU), Mansoura, Egypt.
Purpose: Acute kidney injury is a sentinel event affecting colorectal cancer patients either as a consequence of surgery or systemic chemotherapy. It is highly correlated with both short and long-term adverse outcomes. This work aimed to study the prevalence, risk factors, and impact on survival of postoperative (PO-AKI) and post-chemotherapy (PC-AKI) after colorectal cancer (CRC) surgery in Egyptian patients.
View Article and Find Full Text PDFAdv Exp Med Biol
January 2025
Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) breast cancers have different genomic architecture and show large-scale gene expression differences consistent with different cellular origins, which is reflected in the luminal (i.e., ER+) versus basal-like (i.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!